ABSTRACT
After a comprehensive analysis and research of ancient books and literatures， we discovered that six Banxia Baizhu Tianma Tang prescriptions have the same name. It was originally created by LI Gao. The idea of composition has a certain inheritance relationship with ZHANG Yuan-su′s Tianma Banxia Tang and Huatan Yuhu Wan， which are recorded in Prescription of Peaceful Benevolent Dispensary. In later generations， four doctors developed five prescriptions of the same name. CHENG Guo-peng of the Qing dynasty reformed the prescription based on the theory of phlegm and dampness. He reduced tonic components based on LI's ideas to strengthen the expectorant function， and then transformed the prescription into two of the same name， one for headache and the other for vertigo. The latter was recorded in the textbook of Chinese Herbal Medicine and The Catalogue of Classic Prescriptions （batch 1）， which has the greatest impact on the contemporary prescriptions. Its composition is Pinelliae Rhizoma Praeparatum Cum Zingbere et Alumine （5.595 g）， Atractylodis Macrocephalae Rhizoma （11.19 g）， Gastrodiae Rhizoma， Poria， Citri Exocarpium Rubrum （each 3.73 g）， Glycyrrhizae Radix et Rhizoma （2 g）， 2 pieces of fresh Zingberis Rhizoma Recens （about 2 g） and 2 Jujubae Fructus. The botanical origin of these herbs is clear， and the dosage of herbs is safe in accordance with the Pharmacopoeia of the People's Republic of China.P. The total amount of each dose is about 37.975 g， while the daily dosage is not far different from that of invention. Since its invention， it has been mainly used in the treatment of phlegm headache and vertigo caused by wind phlegm disturbance. In modern clinical practice， it is widely used in treating various diseases with vertigo and headache as the main symptoms， mainly including hypertension， acute ischemic stroke， vertebrobasilar insufficiency， cervical spondylosis， primary headache， Meniere's disease and benign paroxysmal positional vertigo. When the syndrome differentiation is consistent with relevant syndrome type with phlegm as the main pathological factor in traditional Chinese medicine， we can modify the prescription as appropriate.
ABSTRACT
Objective:To explore the molecular mechanism of Banxia Baizhu Tianma Tang in treating hypertension. Method:Based on an internet-based computation platform for integrated pharmacology of traditional Chinese medicine(TCM),TCM prescription database,TCM database,TCM component database and disease/symptoms target database,information on the chemical compositions contained in TCM was retrieved,an interaction network between potential targets and disease targets of Banxia Baizhu Tianma Tang was built,then core target was enriched and calculated,gene function and pathway analysis was carried out,the multi-dimensional relationship network of "Chinese herbs-ingredients-critical targets-key pathways" of Banxia Baizhu Tianma Tang was further constructed. Result:A total of 90 active ingredients in Banxia Baizhu Tianma Tang were obtained,including alkaloids,nucleosides,flavonoids,saponins,organic acids and other ingredients;they involved 287 core targets,including 13 direct targets,such as adenylate cyclase,G protein coupled with β1 receptor,glucose kinase,etc;they also involved nervous system,endocrine system,circulatory system,estrogen signaling pathway,chemokine signaling pathway and other related biological processes and signaling pathways. Conclusion:Banxia Baizhu Tianma Tang can regulate neurotransmitter concentration and activity abnormalities,improve the protective effect of vascular endothelial cells by improving insulin resistance,regulating the production of inflammatory factors,and inhibiting inflammatory reactions,thereby exerting pharmacological effects on the treatment of hypertension.This study can provide a scientific basis for comprehensive interpretation of mechanism of Banxia Baizhu Tianma Tang.
ABSTRACT
Although Banxia Baizhu Tianma Tang (BBT) has been long administered for hypertensive treatment in Traditional Chinese Medicine (TCM), the ratio of the herbal components that makes up the formulation has not been optimized with respect to the anti-hypertensive effect that it inherently possesses. A newly amended BBT (ABBT) formulation was developed using the evidence-based approach of orthogonal stimulus-response compatibility model. The ABBT showed enhanced therapeutic effect while maintaining its traditional theoretical approach rooted in TCM. This study was designed to investigate the possible mechanism of actions involved in the vasodilatory activity of ABBT-50 by evaluating its vasodilative effect on isolated Sprague Dawley rats in the presence of absence of various antagonists. When pre-contracted with phenylephrine, relaxation was observed in endothelium intact (EC50=0.027±0.003mg/ml, Rmax=109.8±2.12%) and denuded aortic rings (EC50=0.409±0.073mg/ml, Rmax=63.15±1.78%), as well as in endothelium intact aortic rings pre-contracted with potassium chloride (EC50=32.7±12.16mg/ml, Rmax=34.02±3.82%). Significant decrease in the vasodilative effect of ABBT-50 was observed in the presence of Nω-nitro-l-arginine methyl ester (EC50=0.12±0.021mg/ml, Rmax=75.33±3.28%), 1H-[1,2,4] Oxadiazolo[4,3-a]quinoxalin-1-one (EC50=0.463±0.18mg/ml, Rmax=54.48±2.02%), methylene blue (EC50=0.19±0.037mg/ml, Rmax=83.69±3.19%), indomethacin (EC50=0.313±0.046mg/ml, Rmax=71.33±4.12%), atropine (EC50=0.146±0.013mg/ml, Rmax=77.2±3.41%), and 4-aminopyridine (EC50=0.045±0.008mg/ml, Rmax=95.55±2.36%). ABBT-50 was also suppressing Ca2+ release from sarcoplasmic reticulum and inhibiting calcium channels. Vasodilatory effects of ABBT-50 are mediated through NO/sGC/cGMP cascade and PGI2, followed by muscarinic pathways and calcium channels.
